SPOP mutation leads to genomic instability in prostate cancer

eLife

Volumn 4, Issue September, 2015, Pages

  Boysen, Gunther ^a,b,e   Barbieri, Christopher E ^a   Prandi, Davide ^c   Blattner, Mirjam ^a   Chae, Sung Suk ^a   Dahija, Arun ^a   Nataraj, Srilakshmi ^a   Huang, Dennis ^a   Marotz, Clarisse ^a   Xu, Limei ^a   Huang, Julie ^a   Lecca, Paola ^c   Chhangawala, Sagar ^a   Liu, Deli ^a   Zhou, Pengbo ^a   Sboner, Andrea ^a,d   Debono, Johann S ^b,e   Demichelis, Francesca ^a,c,d   Houvras, Yariv ^a   Rubin, Mark A ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF TRENTO   (Italy)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e Royal Marsden   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROTEIN; SPECKLE TYPE POZ PROTEIN; UNCLASSIFIED DRUG; VELIPARIB; MUTAGENIC AGENT; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SPOP PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS ASSAY; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION ASSAY; CELL SELECTION; CELL SURVIVAL; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; GENETIC TRANSFECTION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROTEIN EXPRESSION; RNA SEQUENCE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL CULTURE; DEFICIENCY; DNA DAMAGE; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE; ZEBRA FISH;

ANIMALS; CELLS, CULTURED; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; GENOMIC INSTABILITY; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTAGENS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; ZEBRAFISH;

EID: 84945923475     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.09207     Document Type: Article

References (37)

1. An J, Wang C, Deng Y, Yu L, Huang H. 2014. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Reports 6:657-669. doi: 10.1016/j.celrep.2014.01.013.
2. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. 2010. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-251. doi: 10.1016/S0140-6736(10)60893-8.
3. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. 2013. Punctuated evolution of prostate cancer genomes. Cell 153:666-677. doi: 10.1016/j.cell.2013.03.021.
4. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. 2012. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics 44: 685-689. doi: 10.1038/ng.2279.
5. Baumann P, Benson FE, West SC. 1996. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87:757-766. doi: 10.1016/S0092-8674(00)81394-X.
6. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905. doi: 10.1038/nature08822.
7. Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, André n O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA. 2014. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16:14-20. doi: 10.1593/neo.131704.
8. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917. doi: 10.1038/nature03443.
9. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI. 2011. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471:513-517. doi: 10.1038/nature09806.
10. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL. 2013. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine 19:1023-1029. doi: 10.1038/nm.3216.
11. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. 1996. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Research 56:3091-3102.
12. Consortium TCGA. 2015. The molecular taxonomy of primary prostate cancer. Cell. Forthcoming.
13. Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA. 2009. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes, Chromosomes & Cancer 48:366-380. doi: 10.1002/gcc.20647.
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921. doi: 10.1038/nature03445.
15. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine 361:123-134. doi: 10.1056/ NEJMoa0900212.
16. Garraway LA, Lander ES. 2013. Lessons from the cancer genome. Cell 153:17-37. doi: 10.1016/j.cell.2013.03.002.
17. Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades N. 2013. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proceedings of the National Academy of Sciences of USA 110:6997-7002. doi: 10.1073/pnas.1304502110.
18. Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades N. 2014. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Research 74:5631-5643. doi: 10.1158/0008-5472.CAN-14-0476.
19. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674. doi: 10.1016/j.cell. 2011.02.013.
20. Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, Murali R, Vickers A, Scardino PT, Sander C, Reuter V, Taylor BS, Sawyers CL. 2014. Copy number alteration burden predicts prostate cancer relapse. Proceedings of the National Academy of Sciences of USA 111: 11139-11144. doi: 10.1073/pnas.1411446111.
21. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RG, Cuppen E, Chen Y, Sawyers CL, Clevers HC. 2014. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159:163-175. doi: 10.1016/j.cell.2014.08.017.
22. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG. 2014. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet Oncology 15: 1521-1532. doi: 10.1016/S1470-2045(14)71021-6.
23. Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J. 2006. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes, Chromosomes & Cancer 45: 1018-1032. doi: 10.1002/gcc.20369.
24. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. 2010. Isolation, cultivation and characterization of adult murine prostate stem cells. Nature Protocols 5:702-713. doi: 10.1038/nprot.2010.11.
25. Panier S, Boulton SJ. 2014. Double-strand break repair: 53BP1 comes into focus. Nature Reviews Molecular Cell Biology 15:7-18. doi: 10.1038/nrm3719.
26. Pierce AJ, Johnson RD, Thompson LH, Jasin M. 1999. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes & Development 13:2633-2638. doi: 10.1101/gad.13.20.2633.
27. Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. 2014. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology 15: 439. doi: 10.1186/s13059-014-0439-6.
28. Pulvers JN, Huttner WB. 2009. Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors. Development 136:1859-1868. doi: 10.1242/dev. 033498.
29. Schiewer MJ, Knudsen KE. 2014. Transcriptional roles of PARP1 in cancer. Molecular Cancer Research 12: 1069-1080. doi: 10.1158/1541-7786.MCR-13-0672.
30. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V. 2004. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proceedings of the National Academy of Sciences of USA 101:7624-7629. doi: 10.1073/pnas.0400726101.
31. Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Privé GG, Carr SA, Garraway LA. 2014. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346:85-89. doi: 10.1126/science.1250255.
32. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648. doi: 10.1126/science.1117679.
33. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. 2010. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244. doi: 10.1016/S0140-6736(10)60892-6.
34. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. 1995. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Research 55: 342-347.
35. Zhang D, Wang H, Sun M, Yang J, Zhang W, Han S, Xu B. 2014a. Speckle-type POZ protein, SPOP, is involved in the DNA damage response. Carcinogenesis 35:1691-1697. doi: 10.1093/carcin/bgu022.
36. Zhang P, Gao K, Tang Y, Jin X, An J, Yu H, Wang H, Zhang Y, Wang D, Huang H, Yu L, Wang C. 2014b. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. Human Mutation 35: 1142-1151. doi: 10.1002/humu.22614.
37. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, Brooks JD. 2005. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. The Prostate 63: 187-197. doi: 10.1002/pros.20158.